Vaxcyte (PCVX) Competitors $32.51 -0.07 (-0.21%) As of 06/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PCVX vs. SMMT, ITCI, GMAB, RDY, ASND, VTRS, QGEN, MRNA, BPMC, and BBIOShould you be buying Vaxcyte stock or one of its competitors? The main competitors of Vaxcyte include Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Viatris (VTRS), Qiagen (QGEN), Moderna (MRNA), Blueprint Medicines (BPMC), and BridgeBio Pharma (BBIO). These companies are all part of the "pharmaceutical products" industry. Vaxcyte vs. Its Competitors Summit Therapeutics Intra-Cellular Therapies Genmab A/S Dr. Reddy's Laboratories Ascendis Pharma A/S Viatris Qiagen Moderna Blueprint Medicines BridgeBio Pharma Vaxcyte (NASDAQ:PCVX) and Summit Therapeutics (NASDAQ:SMMT) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, media sentiment, analyst recommendations, dividends, profitability, risk, institutional ownership and earnings. Which has more risk and volatility, PCVX or SMMT? Vaxcyte has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500. Comparatively, Summit Therapeutics has a beta of -1.06, indicating that its stock price is 206% less volatile than the S&P 500. Do analysts rate PCVX or SMMT? Vaxcyte presently has a consensus target price of $136.50, suggesting a potential upside of 319.87%. Summit Therapeutics has a consensus target price of $35.09, suggesting a potential upside of 64.90%. Given Vaxcyte's stronger consensus rating and higher probable upside, equities analysts plainly believe Vaxcyte is more favorable than Summit Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vaxcyte 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 3.10Summit Therapeutics 2 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.77 Does the media favor PCVX or SMMT? In the previous week, Summit Therapeutics had 6 more articles in the media than Vaxcyte. MarketBeat recorded 8 mentions for Summit Therapeutics and 2 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 1.71 beat Summit Therapeutics' score of 0.82 indicating that Vaxcyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vaxcyte 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Summit Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better earnings & valuation, PCVX or SMMT? Summit Therapeutics has higher revenue and earnings than Vaxcyte. Summit Therapeutics is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVaxcyteN/AN/A-$463.93M-$3.99-8.15Summit Therapeutics$700K22,577.17-$221.32M-$0.34-62.59 Do insiders and institutionals hold more shares of PCVX or SMMT? 96.8% of Vaxcyte shares are owned by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are owned by institutional investors. 3.1% of Vaxcyte shares are owned by company insiders. Comparatively, 84.9% of Summit Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Is PCVX or SMMT more profitable? Vaxcyte's return on equity of -17.12% beat Summit Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets VaxcyteN/A -17.12% -16.26% Summit Therapeutics N/A -62.87%-51.61% SummaryVaxcyte beats Summit Therapeutics on 8 of the 14 factors compared between the two stocks. Get Vaxcyte News Delivered to You Automatically Sign up to receive the latest news and ratings for PCVX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PCVX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PCVX vs. The Competition Export to ExcelMetricVaxcyteMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.20B$2.84B$5.45B$8.90BDividend YieldN/A2.70%5.36%4.13%P/E Ratio-8.1521.1526.3919.66Price / SalesN/A259.49406.95110.26Price / CashN/A41.2925.8827.49Price / Book1.237.247.925.42Net Income-$463.93M-$55.05M$3.15B$248.34M7 Day Performance-4.63%-1.01%0.66%0.82%1 Month Performance-0.28%5.98%4.95%5.01%1 Year Performance-57.75%0.83%32.31%18.10% Vaxcyte Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PCVXVaxcyte1.8804 of 5 stars$32.51-0.2%$136.50+319.9%-56.9%$4.20BN/A-8.15160Positive NewsSMMTSummit Therapeutics2.6265 of 5 stars$20.39-0.8%$35.09+72.1%+172.8%$15.14B$700K-59.97110Analyst UpgradeITCIIntra-Cellular Therapies0.9036 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560GMABGenmab A/S3.9789 of 5 stars$20.68-2.3%$39.17+89.4%-17.8%$13.26B$3.12B11.752,682Positive NewsHigh Trading VolumeRDYDr. Reddy's Laboratories2.7959 of 5 stars$15.31+0.5%$16.95+10.7%-1.4%$12.78B$3.81B23.2027,811ASNDAscendis Pharma A/S3.5148 of 5 stars$175.78-0.6%$220.67+25.5%+26.6%$10.75B$393.54M-27.991,017Positive NewsVTRSViatris3.0024 of 5 stars$8.85-0.2%$10.40+17.5%-16.0%$10.39B$14.74B-2.7932,000QGENQiagen3.7171 of 5 stars$46.72-0.1%$47.74+2.2%+20.3%$10.39B$2.00B117.145,765MRNAModerna4.5176 of 5 stars$25.67-0.9%$46.61+81.6%-76.8%$9.93B$3.14B-2.945,800Trending NewsGap UpBPMCBlueprint Medicines1.7234 of 5 stars$128.40+0.2%$128.06-0.3%+18.9%$8.29B$508.82M-51.98640Positive NewsHigh Trading VolumeBBIOBridgeBio Pharma4.6848 of 5 stars$42.17+1.1%$56.67+34.4%+70.5%$8.01B$127.42M-11.95400Analyst ForecastInsider Trade Related Companies and Tools Related Companies Summit Therapeutics Competitors Intra-Cellular Therapies Competitors Genmab A/S Competitors Dr. Reddy's Laboratories Competitors Ascendis Pharma A/S Competitors Viatris Competitors Qiagen Competitors Moderna Competitors Blueprint Medicines Competitors BridgeBio Pharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PCVX) was last updated on 7/1/2025 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredGold prediction: $5,000/oz. or higher is comingThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredNvidia’s Huang: AI is going to need 100x more power12Nvidia CEO Jensen Huang didn't mince words. After Nvidia's latest earnings call, Huang said AI now requires...Weiss Ratings | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxcyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaxcyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
